GFAP-eArch 3.0-EYFP AAV (Serotype 9)

GFAP-eArch 3.0-EYFP AAV (serotype 9) is a cutting-edge tool for neuroscience research that combines advanced genetic engineering with a precise viral vector delivery system. This pre-made adeno-associated virus (AAV) particle is genetically engineered to express eArch 3.0-EYFP under the control of the GFAP promoter and is designed for glial cell research applications. eArch 3.0, as a third-generation anion channelrhodopsin, ensures its efficient and stable inhibition under light. It allows researchers to optically control cellular activities with greater precision and efficiency, providing clearer insights into the complex interactions in neural circuits.

AAV serotype 9 ensures its wide spread and efficient transduction, especially within the central nervous system, making it the best choice for targeting neurons and glial cells. The tropism of serotype 9 for neural tissue enhances the delivery of the eArch 3.0-EYFP vector, ensuring a high proportion of target cells express the gene of interest. Additionally, the GFAP promoter is able to drive expression in astrocytes, the major glial cell type in the brain. This specificity makes the GFAP-eArch 3.0-EYFP AAV a powerful tool for astrocyte research, allowing scientists to study the role of these cells in health and disease, especially in neurodegenerative diseases and brain injury.